{ "source": "Nasdaq Nordic Company News", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "status": "retrieved", "company": "Hansa Biopharma", "reports": [ { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T11:38:24Z", "company": "Hansa Biopharma AB", "title": "Hansa Biopharma rapporterar finansiella resultat för andra kvartalet och första halvåret 2026", "category": "Halvårsrapport", "date": "2026-07-22", "language": "sv", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q2", "period": "2026-q2", "report_key": "2026:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=bede0d6ca3a696c58e3598e2e00f28e88&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2026-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2026-q2\\release.txt", "attachments": [ { "label": "07210802.pdf", "url": "https://attachment.news.eu.nasdaq.com/a459bffc7616fe23ccdb6934b4a8e0002", "final_url": "https://attachment.news.eu.nasdaq.com/a459bffc7616fe23ccdb6934b4a8e0002", "filename": "07210802.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2026-q2\\07210802.pdf", "content_type": "application/pdf", "size": 1068755, "sha256": "7c96a3f10c9c5b538cb7ee4f047d7edb9ec0e39e0c83068947e292c0981fd717", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2026-q2\\07210802.pdf", "filename": "07210802.pdf", "extension": ".pdf", "size": 1068755, "sha256": "7c96a3f10c9c5b538cb7ee4f047d7edb9ec0e39e0c83068947e292c0981fd717", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2026-q2\\extracted\\07210802\\07210802.txt", "text_chars": 76479, "metadata": { "page_count": 16, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2026-q2\\extracted\\07210802\\07210802.extraction.json" } } ], "announcement_id": "1455183", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T11:38:25Z", "company": "Hansa Biopharma AB", "title": "Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för Q1 2026", "category": "Nyheter för investerare", "date": "2026-04-08", "language": "sv", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q1", "period": "2026-q1", "report_key": "2026:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b6e7ae8326227671800994d5edd916f72&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2026-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2026-q1\\release.txt", "attachments": [ { "label": "04086073.pdf", "url": "https://attachment.news.eu.nasdaq.com/ab155000ddcd14b8fb922b451c6cde179", "final_url": "https://attachment.news.eu.nasdaq.com/ab155000ddcd14b8fb922b451c6cde179", "filename": "04086073.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2026-q1\\04086073.pdf", "content_type": "application/pdf", "size": 168843, "sha256": "c8671a4d0e0bbf857b977456e4768af01c5bbb9e09f80e63c69414c2cb028229", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2026-q1\\04086073.pdf", "filename": "04086073.pdf", "extension": ".pdf", "size": 168843, "sha256": "c8671a4d0e0bbf857b977456e4768af01c5bbb9e09f80e63c69414c2cb028229", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2026-q1\\extracted\\04086073\\04086073.txt", "text_chars": 2749, "metadata": { "page_count": 2, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2026-q1\\extracted\\04086073\\04086073.extraction.json" } } ], "announcement_id": "1433049", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T11:38:50Z", "company": "Hansa Biopharma AB", "title": "Hansa Biopharma publicerar årsrapport och hållbarhetsredovisning för 2025", "category": "Bokslut och Verksamhetsberättelse", "date": "2026-03-26", "language": "sv", "report_type": "annual-report", "fiscal_year": 2025, "quarter": "annual", "period": "2025-annual", "report_key": "2025:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=bf27172f754e60a7443d9e24540f4d734&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-annual\\release.txt", "attachments": [ { "label": "Hansa Biopharma Hallbarhetsrapport 2025.pdf", "url": "https://attachment.news.eu.nasdaq.com/a4e84c3ce64ec892ffc5f2da6d9615011", "final_url": "https://attachment.news.eu.nasdaq.com/a4e84c3ce64ec892ffc5f2da6d9615011", "filename": "Hansa_Biopharma_Hallbarhetsrapport_2025.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-annual\\Hansa_Biopharma_Hallbarhetsrapport_2025.pdf", "content_type": "application/pdf", "size": 12053607, "sha256": "02eebf0918f2ffcd457f7ce0741f29bba38330c706ab2ee09f8efd30f7c83ce4", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-annual\\Hansa_Biopharma_Hallbarhetsrapport_2025.pdf", "filename": "Hansa_Biopharma_Hallbarhetsrapport_2025.pdf", "extension": ".pdf", "size": 12053607, "sha256": "02eebf0918f2ffcd457f7ce0741f29bba38330c706ab2ee09f8efd30f7c83ce4", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-annual\\extracted\\Hansa_Biopharma_Hallbarhetsrapport_2025\\Hansa_Biopharma_Hallbarhetsrapport_2025.txt", "text_chars": 18504, "metadata": { "page_count": 12, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-annual\\extracted\\Hansa_Biopharma_Hallbarhetsrapport_2025\\Hansa_Biopharma_Hallbarhetsrapport_2025.extraction.json" } }, { "label": "03250515.pdf", "url": "https://attachment.news.eu.nasdaq.com/a634d4bb5de3a51fc56afb8522e487534", "final_url": "https://attachment.news.eu.nasdaq.com/a634d4bb5de3a51fc56afb8522e487534", "filename": "03250515.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-annual\\03250515.pdf", "content_type": "application/pdf", "size": 12918878, "sha256": "49d9d9919d0f1c9d567aee93c741fe03ebaaa671400b2892eb7a627a0bae2392", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-annual\\03250515.pdf", "filename": "03250515.pdf", "extension": ".pdf", "size": 12918878, "sha256": "49d9d9919d0f1c9d567aee93c741fe03ebaaa671400b2892eb7a627a0bae2392", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-annual\\extracted\\03250515\\03250515.txt", "text_chars": 445539, "metadata": { "page_count": 116, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-annual\\extracted\\03250515\\03250515.extraction.json" } } ], "announcement_id": "1428996", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T11:38:54Z", "company": "Hansa Biopharma AB", "title": "Hansa Biopharma rapporterar finansiella resultat för fjärde kvartalet och helåret 2025", "category": "Bokslutskommuniké", "date": "2026-02-11", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2025, "quarter": "q4", "period": "2025-q4", "report_key": "2025:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b24e4656c195e7fa770fa95c24b679f75&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q4\\release.txt", "attachments": [ { "label": "02109163.pdf", "url": "https://attachment.news.eu.nasdaq.com/a55f1a964f145fc4af177885d12b6d83b", "final_url": "https://attachment.news.eu.nasdaq.com/a55f1a964f145fc4af177885d12b6d83b", "filename": "02109163.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q4\\02109163.pdf", "content_type": "application/pdf", "size": 2361928, "sha256": "d1223c9b80e05d8e24cc6206176c82ee7c77a707cce1d8869d5739d07625970b", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q4\\02109163.pdf", "filename": "02109163.pdf", "extension": ".pdf", "size": 2361928, "sha256": "d1223c9b80e05d8e24cc6206176c82ee7c77a707cce1d8869d5739d07625970b", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q4\\extracted\\02109163\\02109163.txt", "text_chars": 72029, "metadata": { "page_count": 16, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q4\\extracted\\02109163\\02109163.extraction.json" } } ], "announcement_id": "1419311", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T11:38:57Z", "company": "Hansa Biopharma AB", "title": "Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för Q3 2025", "category": "Nyheter för investerare", "date": "2025-10-08", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q3", "period": "2025-q3", "report_key": "2025:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=bcc4d4002a3afac4613c92cf153fcffe6&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q3\\release.txt", "attachments": [ { "label": "10080337.pdf", "url": "https://attachment.news.eu.nasdaq.com/a3590db052477e7010a784d8beedc6948", "final_url": "https://attachment.news.eu.nasdaq.com/a3590db052477e7010a784d8beedc6948", "filename": "10080337.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q3\\10080337.pdf", "content_type": "application/pdf", "size": 149251, "sha256": "81d8dd5069731af167e9477ed92479d1f82820bad7be0d1cc700ce44afcd146d", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q3\\10080337.pdf", "filename": "10080337.pdf", "extension": ".pdf", "size": 149251, "sha256": "81d8dd5069731af167e9477ed92479d1f82820bad7be0d1cc700ce44afcd146d", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q3\\extracted\\10080337\\10080337.txt", "text_chars": 2668, "metadata": { "page_count": 2, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q3\\extracted\\10080337\\10080337.extraction.json" } } ], "announcement_id": "1393395", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T11:39:05Z", "company": "Hansa Biopharma AB", "title": "Hansa Biopharma redovisar resultat för andra kvartalet och delårsperioden januari-juni 2025", "category": "Halvårsrapport", "date": "2025-07-17", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q2", "period": "2025-q2", "report_key": "2025:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=be59a800fb78e95341ebbb7d2d873cccc&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q2\\release.txt", "attachments": [ { "label": "07160514.pdf", "url": "https://attachment.news.eu.nasdaq.com/a2bd7541ee4c7707a91027cb2363ce721", "final_url": "https://attachment.news.eu.nasdaq.com/a2bd7541ee4c7707a91027cb2363ce721", "filename": "07160514.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q2\\07160514.pdf", "content_type": "application/pdf", "size": 1723475, "sha256": "95329c9a7d31ef1580cad5cdec7d71cd76582fbd8615f73a353ea1ad9fe0fde6", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q2\\07160514.pdf", "filename": "07160514.pdf", "extension": ".pdf", "size": 1723475, "sha256": "95329c9a7d31ef1580cad5cdec7d71cd76582fbd8615f73a353ea1ad9fe0fde6", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q2\\extracted\\07160514\\07160514.txt", "text_chars": 74346, "metadata": { "page_count": 16, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q2\\extracted\\07160514\\07160514.extraction.json" } } ], "announcement_id": "1379500", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T11:39:07Z", "company": "Hansa Biopharma AB", "title": "Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för Q1 2025", "category": "Nyheter för investerare", "date": "2025-04-03", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q1", "period": "2025-q1", "report_key": "2025:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=bd966d7a0e436df1dde6f6d4892e81388&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q1\\release.txt", "attachments": [ { "label": "04021269.pdf", "url": "https://attachment.news.eu.nasdaq.com/a613ec82fbb278a21614a73ef93f20139", "final_url": "https://attachment.news.eu.nasdaq.com/a613ec82fbb278a21614a73ef93f20139", "filename": "04021269.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q1\\04021269.pdf", "content_type": "application/pdf", "size": 100194, "sha256": "9757e217aebb392fd75b36a374dc4017532db1289f8b5faac734b3a2c7b686a0", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q1\\04021269.pdf", "filename": "04021269.pdf", "extension": ".pdf", "size": 100194, "sha256": "9757e217aebb392fd75b36a374dc4017532db1289f8b5faac734b3a2c7b686a0", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q1\\extracted\\04021269\\04021269.txt", "text_chars": 2581, "metadata": { "page_count": 1, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2025-q1\\extracted\\04021269\\04021269.extraction.json" } } ], "announcement_id": "1353370", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T11:39:22Z", "company": "Hansa Biopharma AB", "title": "Hansa Biopharma publicerar årsredovisning och hållbarhetsredovisning för 2024", "category": "Bokslut och Verksamhetsberättelse", "date": "2025-03-21", "language": "sv", "report_type": "annual-report", "fiscal_year": 2024, "quarter": "annual", "period": "2024-annual", "report_key": "2024:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=b3f66e0760f0e5922e3d1f4e76da660ff&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-annual\\release.txt", "attachments": [ { "label": "03193018.pdf", "url": "https://attachment.news.eu.nasdaq.com/aa901e5d2cd9ac8b3aaa9618272fc2b8b", "final_url": "https://attachment.news.eu.nasdaq.com/aa901e5d2cd9ac8b3aaa9618272fc2b8b", "filename": "03193018.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-annual\\03193018.pdf", "content_type": "application/pdf", "size": 2797915, "sha256": "7c540e35d6f3f4a0e40aa1e081539f9730535717e44ef61bda852af2bc5cbc9e", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-annual\\03193018.pdf", "filename": "03193018.pdf", "extension": ".pdf", "size": 2797915, "sha256": "7c540e35d6f3f4a0e40aa1e081539f9730535717e44ef61bda852af2bc5cbc9e", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-annual\\extracted\\03193018\\03193018.txt", "text_chars": 360363, "metadata": { "page_count": 101, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-annual\\extracted\\03193018\\03193018.extraction.json" } } ], "announcement_id": "1350501", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T11:39:27Z", "company": "Hansa Biopharma AB", "title": "Hansa Biopharmas bokslutskommuniké för januari-december 2024", "category": "Bokslutskommuniké", "date": "2025-02-06", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2024, "quarter": "q4", "period": "2024-q4", "report_key": "2024:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=baf73910900f71907e73a2e06e810b725&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q4\\release.txt", "attachments": [ { "label": "02052870.pdf", "url": "https://attachment.news.eu.nasdaq.com/ae2fb4bf053952c35f5cf2df99b8852a3", "final_url": "https://attachment.news.eu.nasdaq.com/ae2fb4bf053952c35f5cf2df99b8852a3", "filename": "02052870.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q4\\02052870.pdf", "content_type": "application/pdf", "size": 1711245, "sha256": "151f7539d9c6f657803854c8f80d46dd7214f9365db2e625dd84242a5350ee94", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q4\\02052870.pdf", "filename": "02052870.pdf", "extension": ".pdf", "size": 1711245, "sha256": "151f7539d9c6f657803854c8f80d46dd7214f9365db2e625dd84242a5350ee94", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q4\\extracted\\02052870\\02052870.txt", "text_chars": 71941, "metadata": { "page_count": 16, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q4\\extracted\\02052870\\02052870.extraction.json" } } ], "announcement_id": "1341113", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T11:39:33Z", "company": "Hansa Biopharma AB", "title": "Hansa Biopharma rapporterar finansiella resultat för tredje kvartalet 2024 och delårsrapport för januari-september 2024", "category": "Interimsrapport", "date": "2024-10-17", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q3", "period": "2024-q3", "report_key": "2024:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=bb5914c933dc4541abbf383b820629d8b&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q3\\release.txt", "attachments": [ { "label": "10163165.pdf", "url": "https://attachment.news.eu.nasdaq.com/a15b7936b44769b5c49ea28b8204c68c9", "final_url": "https://attachment.news.eu.nasdaq.com/a15b7936b44769b5c49ea28b8204c68c9", "filename": "10163165.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q3\\10163165.pdf", "content_type": "application/pdf", "size": 1640655, "sha256": "53111b306a1871a47c7508f7de23599732427a104cc3e3b24b94a19c575da595", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q3\\10163165.pdf", "filename": "10163165.pdf", "extension": ".pdf", "size": 1640655, "sha256": "53111b306a1871a47c7508f7de23599732427a104cc3e3b24b94a19c575da595", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q3\\extracted\\10163165\\10163165.txt", "text_chars": 68578, "metadata": { "page_count": 15, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q3\\extracted\\10163165\\10163165.extraction.json" } } ], "announcement_id": "1321794", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T11:39:36Z", "company": "Hansa Biopharma AB", "title": "Hansa Biopharma rapporterar finansiella resultat för andra kvartalet 2024 och ger en verksamhetsuppdatering", "category": "Halvårsrapport", "date": "2024-07-18", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q2", "period": "2024-q2", "report_key": "2024:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=bef02c2bdd58381750da47d55f83e0a9c&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q2\\release.txt", "attachments": [ { "label": "07176835.pdf", "url": "https://attachment.news.eu.nasdaq.com/a91de3c49fc04dfc22b6a52fd9d24b0bc", "final_url": "https://attachment.news.eu.nasdaq.com/a91de3c49fc04dfc22b6a52fd9d24b0bc", "filename": "07176835.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q2\\07176835.pdf", "content_type": "application/pdf", "size": 887025, "sha256": "0611d6c9b6d265cd14379e5db790a6d2d0c06a59f0a3049c870534620b1f89a0", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q2\\07176835.pdf", "filename": "07176835.pdf", "extension": ".pdf", "size": 887025, "sha256": "0611d6c9b6d265cd14379e5db790a6d2d0c06a59f0a3049c870534620b1f89a0", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q2\\extracted\\07176835\\07176835.txt", "text_chars": 70776, "metadata": { "page_count": 17, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q2\\extracted\\07176835\\07176835.extraction.json" } } ], "announcement_id": "1306967", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T11:39:44Z", "company": "Hansa Biopharma AB", "title": "Hansa Biopharmas delårsrapport för januari-mars 2024", "category": "Interimsrapport", "date": "2024-04-18", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q1", "period": "2024-q1", "report_key": "2024:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b8a78401bd6b6f50fc99a2eea679a25be&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q1\\release.txt", "attachments": [ { "label": "04173308.pdf", "url": "https://attachment.news.eu.nasdaq.com/a244337ed6b472b581999f12183b6b20d", "final_url": "https://attachment.news.eu.nasdaq.com/a244337ed6b472b581999f12183b6b20d", "filename": "04173308.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q1\\04173308.pdf", "content_type": "application/pdf", "size": 8410999, "sha256": "0e9ae5296cff8282e0304d048ef7bb227ddadb4471c70535a7c9245c4e27b6d0", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q1\\04173308.pdf", "filename": "04173308.pdf", "extension": ".pdf", "size": 8410999, "sha256": "0e9ae5296cff8282e0304d048ef7bb227ddadb4471c70535a7c9245c4e27b6d0", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q1\\extracted\\04173308\\04173308.txt", "text_chars": 65947, "metadata": { "page_count": 16, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2024-q1\\extracted\\04173308\\04173308.extraction.json" } } ], "announcement_id": "1288618", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T11:39:45Z", "company": "Hansa Biopharma AB", "title": "Hansa Biopharma förväntar sig stark försäljningsutveckling under första kvartalet 2024", "category": "Bokslutskommuniké", "date": "2024-04-02", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2023, "quarter": "q4", "period": "2023-q4", "report_key": "2023:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=bb817408be4d6efd33bd1a29052930c3d&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q4\\release.txt", "attachments": [ { "label": "04014780.pdf", "url": "https://attachment.news.eu.nasdaq.com/a2e5ffea0a02f73d653940969caf5f244", "final_url": "https://attachment.news.eu.nasdaq.com/a2e5ffea0a02f73d653940969caf5f244", "filename": "04014780.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q4\\04014780.pdf", "content_type": "application/pdf", "size": 231331, "sha256": "58dcb731cbfae3151f20aa822b0f2491697a1ff6c3e1457b02e30c125eeef6dc", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q4\\04014780.pdf", "filename": "04014780.pdf", "extension": ".pdf", "size": 231331, "sha256": "58dcb731cbfae3151f20aa822b0f2491697a1ff6c3e1457b02e30c125eeef6dc", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q4\\extracted\\04014780\\04014780.txt", "text_chars": 4591, "metadata": { "page_count": 2, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q4\\extracted\\04014780\\04014780.extraction.json" } } ], "announcement_id": "1284919", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T11:40:17Z", "company": "Hansa Biopharma AB", "title": "Hansa Biopharma publicerar årsredovisning och hållbarhetsrapport för 2023", "category": "Bokslut och Verksamhetsberättelse", "date": "2024-03-21", "language": "sv", "report_type": "annual-report", "fiscal_year": 2023, "quarter": "annual", "period": "2023-annual", "report_key": "2023:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=bd0aeb8c037245bb23b27782525f84674&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-annual\\release.txt", "attachments": [ { "label": "03198022.pdf", "url": "https://attachment.news.eu.nasdaq.com/ac2ec62f7431c2add29251f632a572de0", "final_url": "https://attachment.news.eu.nasdaq.com/ac2ec62f7431c2add29251f632a572de0", "filename": "03198022.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-annual\\03198022.pdf", "content_type": "application/pdf", "size": 7844343, "sha256": "fb8b5f620dbe4273367fc8d969b17cd231b9aafa532176edf7ac960661aa5224", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-annual\\03198022.pdf", "filename": "03198022.pdf", "extension": ".pdf", "size": 7844343, "sha256": "fb8b5f620dbe4273367fc8d969b17cd231b9aafa532176edf7ac960661aa5224", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-annual\\extracted\\03198022\\03198022.txt", "text_chars": 353279, "metadata": { "page_count": 105, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-annual\\extracted\\03198022\\03198022.extraction.json" } } ], "announcement_id": "1282632", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T11:40:21Z", "company": "Hansa Biopharma AB", "title": "Hansa Biopharmas delårsrapport januari-september 2023", "category": "Interimsrapport", "date": "2023-10-26", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q3", "period": "2023-q3", "report_key": "2023:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b2040e3695cb897029553b8c36c2dbbe1&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q3\\release.txt", "attachments": [ { "label": "10251421.pdf", "url": "https://attachment.news.eu.nasdaq.com/ae94c624f4ac4255a0a806a1066b6beb7", "final_url": "https://attachment.news.eu.nasdaq.com/ae94c624f4ac4255a0a806a1066b6beb7", "filename": "10251421.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q3\\10251421.pdf", "content_type": "application/pdf", "size": 11838977, "sha256": "5514d6c77dab35b5fc1d89254e52c8d4288ab1a10a00751190267751d9cb030a", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q3\\10251421.pdf", "filename": "10251421.pdf", "extension": ".pdf", "size": 11838977, "sha256": "5514d6c77dab35b5fc1d89254e52c8d4288ab1a10a00751190267751d9cb030a", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q3\\extracted\\10251421\\10251421.txt", "text_chars": 63461, "metadata": { "page_count": 16, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q3\\extracted\\10251421\\10251421.extraction.json" } } ], "announcement_id": "1254900", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T11:40:25Z", "company": "Hansa Biopharma AB", "title": "Hansa Biopharmas halvårsrapport januari-juni 2023", "category": "Halvårsrapport", "date": "2023-07-20", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q2", "period": "2023-q2", "report_key": "2023:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b00495dcd2f0ed6e15197ea39e54c3193&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q2\\release.txt", "attachments": [ { "label": "07195864.pdf", "url": "https://attachment.news.eu.nasdaq.com/aa98541d31c2230c51e17bbf59b28fc40", "final_url": "https://attachment.news.eu.nasdaq.com/aa98541d31c2230c51e17bbf59b28fc40", "filename": "07195864.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q2\\07195864.pdf", "content_type": "application/pdf", "size": 2435837, "sha256": "13def23a6a8ea0e34bade469c95719c3eaffdd413e934a5fd2e1a68b31488247", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q2\\07195864.pdf", "filename": "07195864.pdf", "extension": ".pdf", "size": 2435837, "sha256": "13def23a6a8ea0e34bade469c95719c3eaffdd413e934a5fd2e1a68b31488247", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q2\\extracted\\07195864\\07195864.txt", "text_chars": 62020, "metadata": { "page_count": 16, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q2\\extracted\\07195864\\07195864.extraction.json" } } ], "announcement_id": "1239170", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-03-nasdaq-cns-annual-period-v5.0.10", "retrieved_at": "2026-08-04T11:40:30Z", "company": "Hansa Biopharma AB", "title": "Hansa Biopharmas delårsrapport för januari-mars 2023", "category": "Interimsrapport", "date": "2023-04-20", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q1", "period": "2023-q1", "report_key": "2023:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b6130baf7050bd3f346ace8e7d36342b0&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q1\\release.txt", "attachments": [ { "label": "04192209.pdf", "url": "https://attachment.news.eu.nasdaq.com/a5e83ef50796120f143d6d264e5861db7", "final_url": "https://attachment.news.eu.nasdaq.com/a5e83ef50796120f143d6d264e5861db7", "filename": "04192209.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q1\\04192209.pdf", "content_type": "application/pdf", "size": 4673392, "sha256": "e6869fb0bb1decdc5f18bf1677e7aa3161bacca0ecabb155b1775fb08aad5f45", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q1\\04192209.pdf", "filename": "04192209.pdf", "extension": ".pdf", "size": 4673392, "sha256": "e6869fb0bb1decdc5f18bf1677e7aa3161bacca0ecabb155b1775fb08aad5f45", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q1\\extracted\\04192209\\04192209.txt", "text_chars": 55710, "metadata": { "page_count": 15, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\hansa-biopharma\\nasdaq-reports\\reports\\2023-q1\\extracted\\04192209\\04192209.extraction.json" } } ], "announcement_id": "1221081", "status": "retrieved" } ], "attempts": [ { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Hansa+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "Hansa Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "6388cb0fbd3fe40158e2822aede2955a371b4bfd34cdeeaee1d3a91b3593b773" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Hansa+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 100, "pagination": "row-offset", "query_text": "Hansa Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "a02066d81c7250a1a2a57c9e603a6f5d667bdd5d457b09ca2598f619a9d92f15" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Hansa+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=200&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 200, "pagination": "row-offset", "query_text": "Hansa Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 58, "new_rows": 58, "total_count": null, "from_cache": false, "body_sha256": "3abd503b7030f0a09409c53425c88e310b47e4f44aaeacc154ed65efe4597a3a" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Hansa+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=258&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 258, "pagination": "row-offset", "query_text": "Hansa Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "afd132af8ffa9e04d9333966b7e8adee9622e14201d297b6d304d8ea4616bbc8" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Hansa+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "Hansa Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 4, "new_rows": 4, "total_count": null, "from_cache": false, "body_sha256": "b46f2bbbc462e54fef31e4ebd9d8cd34f3b3672fe09a16f10632f7bf57c39d7d" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Hansa+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=4&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 4, "pagination": "row-offset", "query_text": "Hansa Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "e27b60cb74ad0e336cee9c3aa3436314395a27959baa132e37b1113a29192eb8" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Hansa+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "Hansa Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "ca2b42f80237228254bb569216b27ed698f9517b2be7fdf76b71205a59012b76" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Hansa+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 100, "pagination": "row-offset", "query_text": "Hansa Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "119dfdb6ff260e9307e0f374a03ff33088ed5f679de4b1a157b0b03b5593c68e" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Hansa+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=200&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 200, "pagination": "row-offset", "query_text": "Hansa Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 60, "new_rows": 60, "total_count": null, "from_cache": false, "body_sha256": "d82ac6175246ddae356e3ff895335efee7d275fe656cf39fd439dd10ff6f9056" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Hansa+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=260&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 260, "pagination": "row-offset", "query_text": "Hansa Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "cd92e76e2d26acb1fe6512746a474a09e146f8e4c1004adbe5e16ca3452cd848" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Hansa+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "Hansa Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 5, "new_rows": 5, "total_count": null, "from_cache": false, "body_sha256": "0416a6004d502cfab174d443fe10b473ea3cfd3da53ee6b79899890f09edf41f" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=Hansa+Biopharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=5&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 5, "pagination": "row-offset", "query_text": "Hansa Biopharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "d97ee824ab5793095b25a383238d191f6e98476d65197a4c886f360e00a0680f" } ], "identity": { "slug": "hnsa", "instrument_id": "TX318650", "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/hnsa?id=TX318650" }, "transport": "ordinary-http", "browser_used": false, "query_text": "Hansa Biopharma", "retrieved_at": "2026-08-04T11:40:30Z" }